Print

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Clinicaltrials.gov identifier:
NCT04970056 (https://clinicaltrials.gov/show/NCT04970056)

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

Study Contact Information:

For additional information, contact:
Contact: Naveen Fawas: 734-665-4108  naveen.fawaz@arborresearch.org
Contact: John Graff, PhD:  734-665-4108  john.graff@arborresearch.org


About the Study

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).

What the Study Involves:

Study participation may include:

The study will enroll people from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE study:

Group 1:

Individuals without personal diagnosis of PDAC meeting any of the following criteria:

Group 2

Individuals without a personal diagnosis  of PDAC meeting any of the following criteria:

Group 3

Group 4

Group 5

Group 6

Individuals with a personal history of PDAC meeting any of the following criteria:

Cyst Group

Please Note: The study does not cover the cost of screening and additional office visits needed to complete the requirement for the study. 

Study Locations

California

Connecticut

Florida

Illinois        

Kansas

Massachusetts

Michigan

Nebraska

New York

Ohio

Oregon

Pennsylvania

Texas

Utah

Virginia

Washington

Additional sites are open in Canada, Israel, Italy, Spain, and the United Kingdom. See clinicaltrials.gov for the full list of open sites.        


This Study is Open To:

The study will enroll people from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE study:

Group 1:

Individuals without personal diagnosis of PDAC meeting any of the following criteria:

Group 2

Individuals without a personal diagnosis  of PDAC meeting any of the following criteria:

Group 3

Group 4

Group 5

Group 6

Individuals with a personal history of PDAC meeting any of the following criteria:

Cyst Group

This Study is Not Open To:

Individuals not meeting the criteria above are not eligible to participate. 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.